|Dr. Maria Fardis||CEO, Pres & Director||1.11M||N/A||1968|
|Mr. Timothy E. Morris||CFO, Principal Accounting Officer, Corp. Sec. & Treasurer||603k||N/A||1962|
|Dr. Frederick G. Vogt Ph.D., Esq.||Gen. Counsel||502.5k||N/A||1974|
|Mr. Howard B. Johnson||Sr. VP of Corp. Devel., Alliance Management & Program Management||N/A||N/A||1960|
|Dr. Friedrich Graf Finckenstein||Chief Medical Officer||N/A||N/A||N/A|
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. The company is also developing LN-145, an autologous adoptive cell therapy to treat cervical and head and neck cancers. It has collaboration agreements with Moffitt, M.D. Anderson Cancer Center, Roswell Park Cancer Institute, MedImmune, and Genocea Biosciences, Inc.; and preclinical research collaboration with the Ohio State University and with Cellectis S.A. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.
Iovance Biotherapeutics, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 6; Compensation: 9.